首页> 外文期刊>International archives of allergy and immunology >Suppression of allergic diarrhea in murine ovalbumin-induced allergic diarrhea model by PG102, a water-soluble extract prepared from Actinidia arguta.
【24h】

Suppression of allergic diarrhea in murine ovalbumin-induced allergic diarrhea model by PG102, a water-soluble extract prepared from Actinidia arguta.

机译:PG102抑制小鼠卵清蛋白诱导的过敏性腹泻模型中的过敏性腹泻,PG102是一种由猕猴桃制备的水溶性提取物。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Allergic reactions to food can involve diarrhea, vomiting, nausea and abnormal pain. PG102 has previously been shown to control various factors involved in allergy pathogenesis, including IgE and various Th1 and Th2 cytokines, in vivo as well as in vitro [Park EJ, et al.: J Allergy Clin Immunol 2005;116:1151-1157; Park EJ, et al.: J Invest Dermatol 2007;127:1154-1160]. These data indicate that PG102 might have antiallergic effects on allergic diarrhea. Here, we investigated whether PG102 could prevent allergic diarrhea in the murine ovalbumin (OVA)-induced allergic diarrhea model. METHODS: BALB/c mice were orally treated with PG102, dexamethasone or water for 9 days on a daily basis, followed by subcutaneous injection with OVA on day 0. Animals were orally administrated with OVA from day 7, 3 times a week, over a period of approximately 20 days. Incidence of diarrhea, serum, OVA-restimulated splenocytes and lamina propria lymphocytes were analyzed. RESULTS: Oral administration of PG102 could suppress the incidence of diarrhea in a murine allergic diarrhea model. The amelioration of allergic diarrhea by PG102 was accompanied with the inhibition of mast cell infiltration into the large intestine. The serum level of IgE, IL-6 and MCP-1 was decreased in PG102-treated mice. When splenocytes were isolated from respective groups and cultured in the presence of OVA, cells from PG102-administrated animals produced lesser amounts of IL-6 and MCP-1. CONCLUSIONS: PG102 has the potential to be used as a preventive for food allergic diseases.
机译:背景:对食物的过敏反应可能会引起腹泻,呕吐,恶心和异常疼痛。 PG102先前已显示在体​​内和体外控制与变态反应的发病机制有关的各种因素,包括IgE以及各种Th1和Th2细胞因子[Park EJ,et al.:J Allergy Clin Immunol 2005; 116:1151-1157; J.Med.Chem.Soc。,2005,5:2]。 Park EJ等人:J Invest Dermatol 2007; 127:1154-1160]。这些数据表明PG102可能对过敏性腹泻有抗过敏作用。在这里,我们调查了PG102是否可以在鼠卵清蛋白(OVA)诱发的过敏性腹泻模型中预防过敏性腹泻。方法:每天对BALB / c小鼠口服PG102,地塞米松或水口服治疗9天,然后在第0天皮下注射OVA。从第7天开始,每周3次口服OVA,每天一次。约20天。分析腹泻,血清,OVA重新刺激的脾细胞和固有层淋巴细胞的发生率。结果:口服PG102可以抑制鼠类过敏性腹泻模型中的腹泻发生率。 PG102改善过敏性腹泻的同时,还抑制了肥大细胞向大肠的浸润。 PG102处理的小鼠的IgE,IL-6和MCP-1的血清水平降低。当从各个组分离脾细胞并在OVA存在下培养时,来自施用PG102的动物的细胞产生较少量的IL-6和MCP-1。结论:PG102有潜力用作食物过敏性疾病的预防剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号